Background
The KRAS oncogene is one of the most frequently mutated oncogenes in human cancers, including pancreatic, lung, and colorectal cancers, and is deeply implicated in tumor proliferation, survival, and metastasis. For many years, KRAS was considered an “undruggable” target due to its complex structure and function. In recent times, nucleic acid-based therapeutics, particularly approaches utilizing siRNA (small interfering RNA), have emerged as promising strategies to overcome this challenging target by directly suppressing KRAS gene expression. For aggressive diseases like locally advanced pancreatic cancer (LAPC) with poor prognoses, innovative therapeutic strategies are urgently needed.
Key Findings / Results
Silexion Therapeutics has announced the initiation of GMP (Good Manufacturing Practice) clinical batch manufacturing for SIL204, its next-generation siRNA therapeutic specifically designed to silence mutated KRAS oncogenes. This manufacturing effort aims to secure the necessary clinical supply for a planned Phase 2/3 clinical trial targeting patients with locally advanced pancreatic cancer (LAPC). Concurrently, the company obtained approval from the Helsinki Ethics Committee of the Tel Aviv Sourasky Medical Center in Israel to proceed with this Phase 2/3 trial. SIL204 adopts an innovative dual-route administration strategy, combining intratumoral delivery to act directly on the primary tumor with systemic administration to address metastatic disease. This approach aims to tackle both local and systemic disease burdens.
The drug substance (API) for SIL204 was manufactured in 2025 by a specialized global oligonucleotide CDMO (Contract Development and Manufacturing Organization). This collaboration ensured the provision of high-quality API, facilitating a swift and seamless transition to drug product formulation. The reliance on this CDMO highlights the specialized nature of nucleic acid drug manufacturing and the importance of partners who can meet stringent technical requirements.
Technical Significance & Outlook
The commencement of GMP clinical supply manufacturing for SIL204 and the approval for its Phase 2/3 clinical trial represent significant milestones in bringing this promising siRNA therapeutic to patients. An siRNA therapeutic approach targeting the KRAS oncogene, previously considered an intractable target, has the potential to usher in a major advancement in cancer treatment. The dual-route administration strategy, combining intratumoral and systemic delivery, offers a distinct advantage over existing approaches by aiming for maximum therapeutic efficacy against both primary tumors and metastatic disease. Future focus will be on the success of the Phase 2/3 trial, demonstrating a favorable safety and efficacy profile in LAPC patients, and navigating the subsequent regulatory approval pathways. Should this drug gain approval, it could offer new hope for treating aggressive cancers like pancreatic cancer.
Comments